Acadian Asset Management LLC Increases Stake in Bioverativ Inc (BIVV)

Acadian Asset Management LLC grew its stake in shares of Bioverativ Inc (NASDAQ:BIVV) by 54.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,246,815 shares of the biotechnology company’s stock after purchasing an additional 441,084 shares during the period. Acadian Asset Management LLC’s holdings in Bioverativ were worth $67,229,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisors Asset Management Inc. acquired a new stake in shares of Bioverativ in the 3rd quarter worth about $137,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Bioverativ in the 3rd quarter worth about $186,000. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of Bioverativ in the 3rd quarter worth about $190,000. Canada Pension Plan Investment Board acquired a new stake in shares of Bioverativ in the 3rd quarter worth about $194,000. Finally, ACG Wealth acquired a new stake in shares of Bioverativ in the 3rd quarter worth about $205,000. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Shares of Bioverativ Inc (BIVV) opened at $62.75 on Friday. Bioverativ Inc has a 52-week low of $40.99 and a 52-week high of $65.09. The stock has a market cap of $6,790.00 and a PE ratio of 15.34.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The business had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The firm’s revenue was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ Inc will post 2.69 EPS for the current year.

A number of research firms recently weighed in on BIVV. Zacks Investment Research lowered shares of Bioverativ from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley restated an “underweight” rating and issued a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Finally, Credit Suisse Group restated a “neutral” rating and issued a $65.00 target price on shares of Bioverativ in a report on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $62.53.

ILLEGAL ACTIVITY NOTICE: “Acadian Asset Management LLC Increases Stake in Bioverativ Inc (BIVV)” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3145125/acadian-asset-management-llc-increases-stake-in-bioverativ-inc-bivv.html.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.